The FDA has authorized use of the Valeda Light Delivery System (LumiThera), a multiwavelength photobiomodulation (PBM) device, to improve visual acuity in patients with dry age-related macular degeneration (AMD) who have best-corrected visual acuity (BCVA) of 20/32 to 20/70.
DRY AMD — About 90% of patients with AMD have the dry (non-neovascular) form, which is characterized by abnormalities of the retinal pigment epithelium with focal accumulation of metabolic byproducts known as drusen. Patients with dry AMD may experience a slow reduction in central vision. Geographic atrophy (GA) is an advanced...
ISSUE
Emrosi (Journey), an oral, low-dose, biphasic-release formulation of the tetracycline antibiotic minocycline, has been approved by the FDA for once-daily treatment of inflammatory lesions of rosacea (papules and pustules) in adults. Low-dose, biphasic-release doxycycline (Oracea, and generics) has been available for years for treatment of papulopustular rosacea.1
STANDARD TREATMENT — Systemic antibiotics are effective for treatment of papules, pustules, and erythema of rosacea, but not for telangiectasia, rhinophyma, or flushing. They are generally used for treatment of moderate to severe disease or disease that has not responded to topical therapy. Effective treatment often requires a prolonged course (months or sometimes years). Low-dose doxycycline causes fewer adverse effects than full antimicrobial doses and has not …